Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
Por:
Galsky, MD, Valderrama, BP, Maruzzo, M, Pous, AF, Ciuleanu, TE, Chatzkel, JA, Koie, T, Hoimes, CJ, Puente, J, Zakharia, Y, Rosenbaum, E, Boehm, K, Loriot, Y, Bedke, J, Wirtz, H, Mihm, M, Huang, QL, Rogiers, J, Moreno, BH and Lista, AGD
Publicada:
1 mar 2026
Resumen:
Filiaciones:
Galsky, MD:
Mt Sinai Tisch Canc Ctr, New York, NY USA
Valderrama, BP:
Hosp Univ Virgen Rocio, Seville, Spain
Maruzzo, M:
Veneto Inst Oncol IOV IRCCS, Oncol Unit 3, Padua, Italy
:
Univ Autonoma Barcelona, Germans Trias & Pujol Univ Hosp, Germans Trias& Pujol Res Inst,Catalan Inst Oncol B, Badalona Appl Res Grp Oncol,Med Oncol Dept, Badalona, Spain
Ciuleanu, TE:
Inst Oncol Prof Dr Ion Chiricuta, Dept Med Oncol, Cluj Napoca, Romania
Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania
Chatzkel, JA:
Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL USA
H Lee Moffitt Canc Ctr & Res Inst, Gainesville, FL USA
Koie, T:
Gifu City Hosp, Gifu, Japan
Hoimes, CJ:
Duke Canc Inst, Durham, NC USA
Puente, J:
Hosp Clin San Carlos, Madrid, Spain
Zakharia, Y:
Mayo Clin Arizona, Div Hematol & Med Oncol, Phoenix, AZ USA
Rosenbaum, E:
Rabin Med Ctr, Petah Tiqwa, Israel
Boehm, K:
Univ Klinikum Carl Gustav Carus, Dresden, Germany
Loriot, Y:
Gustave Roussy Canc Inst, Paris, France
Bedke, J:
Klinikum Stuttgart, Eva Mayr Stihl Canc Ctr, Stuttgart, Germany
Wirtz, H:
Pfizer Inc, Bothell, WA USA
Mihm, M:
Astellas Pharma Inc, Northbrook, IL USA
Huang, QL:
Merck & Co Inc, Rahway, NJ USA
Rogiers, J:
Merck & Co Inc, Rahway, NJ USA
Moreno, BH:
Merck & Co Inc, Rahway, NJ USA
Lista, AGD:
Univ Las Palmas Gran Canaria, Complejo Hosp Univ Insular Materno Infantil, Med Oncol Dept, Las Palmas Gran Canaria, Spain
|